These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23633554)

  • 21. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
    Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting.
    DiLuigi AJ; Engmann L; Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2010 Aug; 94(3):1111-4. PubMed ID: 20074722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
    Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
    Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related.
    Shapiro BS; Andersen CY
    Fertil Steril; 2015 Apr; 103(4):874-8. PubMed ID: 25707333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.
    Engmann L; Benadiva C
    Fertil Steril; 2012 Mar; 97(3):531-3. PubMed ID: 22245529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study.
    Muñoz M; Cruz M; Humaidan P; Garrido N; Pérez-Cano I; Meseguer M
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):167-72. PubMed ID: 23351671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Is it possible to avoid working on weekends in an Assisted Reproductive Technology program?].
    Belaisch-Allart J; Mayenga JM; Grzegorczyk-Martin V; Grefenstette I; Chouraqui A; Belaid Y; Kulski O
    Gynecol Obstet Fertil; 2012 Sep; 40(9):472-5. PubMed ID: 22901781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
    Kashyap S; Parker K; Cedars MI; Rosenwaks Z
    Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'GnRH agonist trigger: looking for the coin under the lamp post?'.
    Kol S
    Hum Reprod; 2006 May; 21(5):1328; author reply 1328-9. PubMed ID: 16611976
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
    Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can FSH co-trigger prevent OHSS?
    Rosen MP; Meldrum DR
    Fertil Steril; 2012 Mar; 97(3):534-5. PubMed ID: 22285746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.
    DiLuigi AJ; Nulsen JC
    Curr Opin Obstet Gynecol; 2007 Jun; 19(3):258-65. PubMed ID: 17495643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.